Cutler Group LP Arvinas, Inc. Call Options Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	SELL	$36.38 - $52.31 $21,828 - $31,386	-600 Reduced 8.96%	6,100 $70,000
Q4 2023 Jan 18, 2024	BUY	$14.19 - $42.33 $95,073 - $283,611	6,700 New	6,700 $85,000
Q2 2021 Jul 19, 2021	SELL	$60.45 - $84.26 $48,360 - $67,408	-800 Reduced 33.33%	1,600 $0
Q1 2021 Apr 26, 2021	BUY	$58.19 - $91.37 $122,199 - $191,877	2,100 Added 700.0%	2,400 $6,000
Q4 2020 Jan 21, 2021	BUY	$20.19 - $84.93 $4,038 - $16,986	200 Added 200.0%	300 $3,000
Q3 2020 Oct 27, 2020	SELL	$22.99 - $36.34 $43,681 - $69,046	-1,900 Reduced 95.0%	100 $0
Q1 2020 May 07, 2020	BUY	$33.0 - $54.5 $66,000 - $109,000	2,000 New	2,000 $10,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.